New drug combo aims to halt returning bone cancer
NCT ID NCT04417062
First seen Feb 28, 2026 · Last updated Apr 29, 2026 · Updated 11 times
Summary
This study tests whether two drugs, olaparib and ceralasertib, can help control osteosarcoma that has come back or not responded to treatment. About 63 people aged 12 to 40 with recurrent osteosarcoma will receive the drug combination. The goal is to see if the treatment can stop the cancer from growing or returning for at least 4 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana Farber Cancer Institite
Boston, Massachusetts, 02115, United States
-
MD Anderson
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering
New York, New York, 10065, United States
-
UCSF Benioff Children's Hospital; UCSF Pediatrics Hematology Oncology
San Francisco, California, 94158, United States
Conditions
Explore the condition pages connected to this study.